NCT03370640View on ClinicalTrials.gov

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions

Schizophrenia

Interventions

DRUG

SEP-363856

An oral 25 or 50mg dose of SEP 363856

Trial Locations (8)

483-8248

Hotei Hospital, Kōnan

243-0201

Soushu Hospital, Atsugi

386-0401

Mental Support SOYOKAZE Hospital, Ueda

590-0018

Asakayama General Hospital, Sakai

157-8577

Showa University Karasuyama Hospital, Setagaya-Ku

175-0091

Narimasu Kosei Hospital, Itabashi-Ku

861-8002

Yuge Hospital, Kumamoto

842-0192

National Hospital Organization Hizen Psychiatric Center, Saga

All Listed Sponsors

lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT03370640 - Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2). | Biotech Hunter | Biotech Hunter